Comparative Effects of Fosinopril and Irbesartan on Haematopoiesis in Essential Hypertensives

Journal of Clinical and Basic Cardiology

Volumn 6, Issue 1-4, 2003, Pages 45-47

  Robles, Nicolás Roberto ^a   Angulo, E ^a   Grois, J ^a   Barquero, A ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Angiotensin; Angiotensin converting enzyme inhibitors; Angiotensin receptor antagonist; Haematopoiesis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; FOSINOPRIL; IRBESARTAN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ERYTHROPOIESIS; ESSENTIAL HYPERTENSION; HEMATOCRIT; HEMATOPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL;

EID: 0346123152     PISSN: 15612775     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Sauron C, Berthoux P, Berthoux F, Alamartine E, Diab N, Groyet C, Hacini J. New insights and treatment in post-transplant polycythemia (erythrocytosis) of renal recipients. Transplant Proc 1993; 25: 1032-3.
2. Julian BA, Gaston RS, Barker CV, Krystal G, Diethelm AG, Curtis JJ. Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis. Kidney Int 1994; 1397-403.
3. Charytan C, Goldfarb-Rumyantzev A, Wang YF, Schwenk MH, Spinowitz BS. Effect of angiotensin-converting enzyme inhibitor of response to erythropoietin therapy in chronic dialysis patients. Am J Nephrol 1998; 18: 498-503.
4. Labeew M, Prost NF, Daoud S, Lapra C, Zech P, Pozet N. Renal venous erythropoietin concentration in hypertensive patients with unilateral renal disease. Nephrol Dial Transplant 1992; 7: 1190-3.
5. Vlahakos DV, Kosmas EN, Dimopoulos I, Ikonomou E, Jullien G, Vassilakos P, Marathias KP. Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am J Med 1999; 106: 158-64.
6. Jensen JD, Eiskjaer H, Bagger JP, Pedersen EB. Elevated serum level of erythropoietin in congestive heart failure related to renal function. J Intern Med 1993;233:125-30.
7. Gould AB, Goodman S, DeWolf R, Onesti G, Swartz C. Interrelation of the renin-angiotensin system and erythropoietin in rats. J Lab Clin Med 1980; 96: 523-34.
8. Nakao K, Shirakura T, Azuma M, Maekawa T. Studies on erythropoietic action of angiotensin II. Blood 1967; 29: 754-60.
9. Hirakata H, Onoyama K, Hori K, Fujishima M. Participation of the renin-angiotensin system in the capropril-induced worsening of anemia in chronic haemodialysis patients. Clin Nephrol 1986; 26: 27-32.
10. Walter J. Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients? Nephrol Dial Transplant 1993; 8: 1428.
11. Danovitch GM, Jamgotchian NJ, Eggena PH, Paul W, Barrett JD, Wilkinson A, Lee DB. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism. Transplantation 1995; 60: 132-7.
12. Torregrosa JV, Campistol JM, Montesinos M, Rogado AG, Oppenheimer F, Andreu J. Efficacy of captopril on posttransplant erythrocytosis. Transplantation 1994; 58: 311-4.
13. Volpe M, Tritto C, Testa U, Rao MA, Martucci C, Mirante A, et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, haemodynamic, and hormonal profiles. Am J Cardiol 1994; 74: 468-73.
14. Sica DA. Pharmacology and clinical efficacy of angiotensin receptor blockers. Am J Hypertens 2001; 14: 242S-247S.
15. Rell K, Koziak K, Jarzyo I, Lao M, Gaciong Z. Correction of posttransplant erythrocytosis with enalapril. Transplantation 1994; 57: 1059-63.
16. Julian BA, Brantley RR, Barker CV, Stopka T, Gaston RS, Curtis JJ, Lee JY, Prchal JT. Losartan, an angiotensin II type 1 receptor antagonist lowers haematocrit in post transplant erythrocitosis. J Am Soc Nephrol 1998; 9: 1104-8
17. Hortal L, Fernandez N, Vega N, Rodriguez JC, Losada A, Lorenzo M, Plaza C, Palop L. Losartan versus ramipril in the treatment of postrenal transplant erythrocitosis. Transplant Proc 1998; 30: 2128-8.
18. Vlahakos DV, Marathias KP, Kosmas EN. Losartan reduces haematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis. Ann Intern Med 2001; 134: 426-7.
19. Glicklich D, Kapoian T, Mian H, Gilman J, Tellis V, Crozat H. Effects of erythropoietin, angiotensin II, and angiotensin converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocitosis. Transplantation 1999; 66: 62-6.
20. Gould AB, Goodman SA, Green D. An in vivo effect of renin on erytliropoietin formation. Lab Invest 1973; 28: 719-22.
21. Anagnosotou A, Baranowski R, Pillay VKG, Kurtzman N, Vercilloti G, Fried W. Effect of renin on extrarenal erythropoietin production. J Lab Clin Med 1976; 88: 707-15.
22. Nakao K, Shirakura T, Azuma M, Maekawa T. Studies on erythropoietic action of angiotensin II. Blood 1967; 29: 754-60.
23. Donnelly S, Shah BR. Erythropoietin deficiency in hyporeninemia. Am J Kidney Dis 1999; 33: 947-53.
24. Mrug M, Stopka K, Julian BA, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100: 2310-4.
25. Wolf G, Neilson E. Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993; 3: 1531-40.